Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal ...

Eli Lilly ( LLY 1.21%) and Novo Nordisk ( NVO 2.66%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.